(VIANEWS) – Trip.com (TCOM), United Therapeutics Corporation (UTHR), Towers Watson & Co (TW) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Trip.com (TCOM)
21.5% sales growth and 9.16% return on equity
Trip.com Group Limited operates as a travel service provider for accommodation reservation, transportation ticketing, packaged tours and in-destination, corporate travel management, and other travel-related services in China and internationally. The company acts as an agent for hotel-related transactions and selling air tickets, as well as provides train, long-distance bus, and ferry tickets; travel insurance products, such as flight delay, air accident, and baggage loss coverage; and air-ticket delivery, online check-in and seat selection, express security screening, real-time flight status tracker, and airport VIP lounge services. It also provides independent leisure travelers bundled packaged-tour products comprising group, semi-group, and customized and packaged tours with various transportation arrangements, including air, cruise, bus, and car rental services. In addition, the company offers integrated transportation and accommodation services; destination transportation and ticket, activity, insurance, visa, and tour guide services; user support, supplier management, and customer relationship management services; and in-destination products and services. Further, it provides its corporate clients with business visit, incentive trip, meeting and conference, travel data collection and analysis, industry benchmark, cost saving analysis, and travel management solutions; and Corporate Travel Management System, an online platform that integrates information management, online booking and authorization, online inquiry, and travel reporting systems. Additionally, the company offers online advertising and financial services. It operates under the Ctrip, Qunar, Trip.com, and Skyscanner brands. The company was formerly known as Ctrip.com International, Ltd. and changed its name to Trip.com Group Limited in October 2019. Trip.com Group Limited was founded in 1999 and is headquartered in Shanghai, the People's Republic of China.
Earnings Per Share
As for profitability, Trip.com has a trailing twelve months EPS of $1.34.
PE Ratio
Trip.com has a trailing twelve months price to earnings ratio of 27.94. Meaning, the purchaser of the share is investing $27.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.16%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 99.4%, now sitting on 39.21B for the twelve trailing months.
Moving Average
Trip.com’s worth is above its 50-day moving average of $35.38 and above its 200-day moving average of $35.58.
Volume
Today’s last reported volume for Trip.com is 1386800 which is 64.65% below its average volume of 3923930.
Previous days news about Trip.com(TCOM)
- According to Zacks on Monday, 5 February, "One other Consumer Discretionary stock that has outperformed the sector so far this year is Trip.com (TCOM Quick QuoteTCOM – Free Report) . ", "On Holding and Trip.com could continue their solid performance, so investors interested in Consumer Discretionary stocks should continue to pay close attention to these stocks."
2. United Therapeutics Corporation (UTHR)
18.7% sales growth and 17.52% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $18.13.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 11.77. Meaning, the purchaser of the share is investing $11.77 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.52%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.1%, now sitting on 2.2B for the twelve trailing months.
3. Towers Watson & Co (TW)
14.6% sales growth and 7.36% return on equity
Tradeweb Markets Inc. builds and operates electronic marketplaces in the Americas, Europe, the Middle East, Africa, Asia Pacific, and internationally. The company's marketplaces facilitate trading in a range of asset classes, including rates, credit, money markets, and equities. It offers pre-trade data and analytics, trade execution, and trade processing, as well as post-trade data, analytics, and reporting services. The company provides flexible order and trading systems to institutional investors. It also offers a range of electronic, voice, and hybrid platforms to dealers and financial institutions on electronic or hybrid markets with Dealerweb platform; and trading solutions for financial advisory firms and traders with Tradeweb Direct platform. The company serves in the institutional, wholesale, and retail client sectors. Its customers include asset managers, hedge funds, insurance companies, central banks, banks and dealers, proprietary trading firms, retail brokerage and financial advisory firms, and regional dealers. The company was founded in 1996 and is headquartered in New York, New York. Tradeweb Markets Inc. operates a subsidiary of Refinitiv Parent Limited.
Earnings Per Share
As for profitability, Towers Watson & Co has a trailing twelve months EPS of $1.72.
PE Ratio
Towers Watson & Co has a trailing twelve months price to earnings ratio of 56.64. Meaning, the purchaser of the share is investing $56.64 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.36%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 30.6% and 18.5%, respectively.
Yearly Top and Bottom Value
Towers Watson & Co’s stock is valued at $97.42 at 00:22 EST, under its 52-week high of $100.24 and way higher than its 52-week low of $64.83.
Moving Average
Towers Watson & Co’s value is above its 50-day moving average of $93.85 and way above its 200-day moving average of $82.18.
Sales Growth
Towers Watson & Co’s sales growth is 26.8% for the ongoing quarter and 14.6% for the next.
4. Axcelis Technologies (ACLS)
12.2% sales growth and 32.8% return on equity
Axcelis Technologies, Inc. designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and Asia Pacific. The company offers high energy, high current, and medium current implanters for various application requirements. It also provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. It sells its equipment and services to semiconductor chip manufacturers through its direct sales force. Axcelis Technologies, Inc. was founded in 1978 and is headquartered in Beverly, Massachusetts.
Earnings Per Share
As for profitability, Axcelis Technologies has a trailing twelve months EPS of $6.98.
PE Ratio
Axcelis Technologies has a trailing twelve months price to earnings ratio of 18.81. Meaning, the purchaser of the share is investing $18.81 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.8%.
5. Alphabet (GOOGL)
11.2% sales growth and 27.36% return on equity
Alphabet Inc. offers various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. It operates through Google Services, Google Cloud, and Other Bets segments. The Google Services segment provides products and services, including ads, Android, Chrome, devices, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube. It is also involved in the sale of apps and in-app purchases and digital content in the Google Play and YouTube; and devices, as well as in the provision of YouTube consumer subscription services. The Google Cloud segment offers infrastructure, cybersecurity, databases, analytics, AI, and other services; Google Workspace that include cloud-based communication and collaboration tools for enterprises, such as Gmail, Docs, Drive, Calendar, and Meet; and other services for enterprise customers. The Other Bets segment sells healthcare-related and internet services. The company was incorporated in 1998 and is headquartered in Mountain View, California.
Earnings Per Share
As for profitability, Alphabet has a trailing twelve months EPS of $5.79.
PE Ratio
Alphabet has a trailing twelve months price to earnings ratio of 24.83. Meaning, the purchaser of the share is investing $24.83 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.36%.
Previous days news about Alphabet(GOOGL)
- According to FXStreet on Monday, 5 February, "In addition to large orders of server chips already scheduled in advance from the world’s biggesthyperscalers, such as Meta Platforms (META), Microsoft (MSFT), Amazon (AMZN) and Alphabet (GOOGL), Hari predicts that heavy demand will stem from product cycles involving the B100 and H200 chips."
- According to Zacks on Saturday, 3 February, "These companies, along with their peers in the ‘Magnificent 7’ group of stocks - Apple (AAPL Quick QuoteAAPL – Free Report) , Alphabet (GOOGL Quick QuoteGOOGL – Free Report) , Tesla (TSLA Quick QuoteTSLA – Free Report) , and Nvidia (NVDA Quick QuoteNVDA – Free Report) - led the market higher last year, and that momentum has continued this year.", "The market wasn’t particularly impressed with the Alphabet and Apple reports, but they came out with Q4 earnings growth of +51.8% and +13.1%, respectively."
- According to FXStreet on Monday, 5 February, "NASDAQ Stock market Elliott Wave analysis and trading strategies: NASDAQ 100, Apple (AAPL), Tesla (TSLA), Amazon (AMZN), Nvidia (NVDA), Microsoft (MSFT), Meta Platforms (META), Netflix (NFLX), Alphabet (GOOGL)"
- According to Zacks on Monday, 5 February, "Currently, Qualys, Alphabet and Infosys carry a Zacks Rank #3 (Hold) each, while Microsoft has a Zacks Rank #2 (Buy). "
6. Gentex Corporation (GNTX)
8.8% sales growth and 19.57% return on equity
Gentex Corporation designs, develops, manufactures, markets, and supplies digital vision, connected car, dimmable glass, and fire protection products in the United States, Germany, Japan, Mexico, and internationally. It operates through Automotive Products and Other segments. The company offers automotive products, including interior and exterior electrochromic automatic-dimming rearview mirrors, automotive electronics, and non-automatic-dimming rearview mirrors for automotive passenger cars, light trucks, pick-up trucks, sport utility vehicles, and vans for original equipment manufacturers, automotive suppliers, and various aftermarket and accessory customers. It also provides variable dimmable windows to aircraft manufacturers and airline operators. In addition, the company offers photoelectric smoke detectors and alarms, electrochemical carbon monoxide alarms and detectors, audible and visual signaling alarms, and bells and speakers used in fire detection systems in office buildings, hotels, and other commercial and residential buildings, as well as researches and develops nanofiber chemical sensing products. The company sells its fire protection products directly, as well as through sales managers and manufacturer representative organizations to fire protection and security product distributors, electrical wholesale houses, and original equipment manufacturers of fire protection systems. Gentex Corporation was incorporated in 1974 and is headquartered in Zeeland, Michigan.
Earnings Per Share
As for profitability, Gentex Corporation has a trailing twelve months EPS of $1.84.
PE Ratio
Gentex Corporation has a trailing twelve months price to earnings ratio of 18.28. Meaning, the purchaser of the share is investing $18.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.57%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 19.3%, now sitting on 2.3B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Gentex Corporation’s EBITDA is 50.76.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jan 3, 2024, the estimated forward annual dividend rate is 0.48 and the estimated forward annual dividend yield is 1.42%.
Yearly Top and Bottom Value
Gentex Corporation’s stock is valued at $33.63 at 00:22 EST, under its 52-week high of $34.33 and way above its 52-week low of $25.77.
7. Columbus McKinnon Corporation (CMCO)
5.8% sales growth and 6.23% return on equity
Columbus McKinnon Corporation designs, manufactures, and markets intelligent motion solutions to ergonomically move, lift, position, and secure materials worldwide. The company offers electric, air-powered, lever, and hand hoists; hoist trolleys, explosion-protected and custom engineered hoists, and winches; crane systems, such as crane components and kits, enclosed track rail systems, mobile and jib cranes, and fall protection systems, as well as material handling solutions; rigging equipment comprising below-the-hook lifting devices, shackles, chains and chains accessories, forestry and hand tools, lifting slings, lashing systems, and tie-downs and load binders; rotary unions and swivel joints; and mechanical and electromechanical actuators. It also provides power and motion technology products, including AC motor controls and line regenerative systems, automation and diagnostics, brakes, cable and festoon systems, collision avoidance systems, conductor bar systems, DC motor and magnet control systems, elevator drives, inverter duty motors, mining drives, pendant pushbutton stations, radio controls, and wind inverters; power delivery subsystems; overhead aluminum light rail workstations; and low profile, flexible chain, large scale, sanitary, and vertical elevation conveyor systems, as well as pallet system conveyors and accumulation systems. The company serves market verticals, including general industries, transportation, energy and utilities, process industries, industrial automation, construction and infrastructure, food and beverage, entertainment, life sciences, consumer packaged goods, and e-commerce/supply chain/warehousing. It offers its products to end users directly, as well as through distributors, independent crane builders, material handling specialists and integrators, government agencies, original equipment manufacturers, and engineering procurement and construction firms. The company was founded in 1875 and is headquartered in Buffalo, New York.
Earnings Per Share
As for profitability, Columbus McKinnon Corporation has a trailing twelve months EPS of $1.77.
PE Ratio
Columbus McKinnon Corporation has a trailing twelve months price to earnings ratio of 21.45. Meaning, the purchaser of the share is investing $21.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.23%.
Sales Growth
Columbus McKinnon Corporation’s sales growth for the next quarter is 5.8%.
Volume
Today’s last reported volume for Columbus McKinnon Corporation is 14760 which is 87.95% below its average volume of 122516.
Moving Average
Columbus McKinnon Corporation’s value is higher than its 50-day moving average of $36.97 and above its 200-day moving average of $36.82.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 5.6% and positive 10% for the next.
8. Haemonetics Corporation (HAE)
5.1% sales growth and 15.81% return on equity
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Earnings Per Share
As for profitability, Haemonetics Corporation has a trailing twelve months EPS of $2.49.
PE Ratio
Haemonetics Corporation has a trailing twelve months price to earnings ratio of 32.84. Meaning, the purchaser of the share is investing $32.84 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.81%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 10.6% and 19.5%, respectively.
Sales Growth
Haemonetics Corporation’s sales growth for the next quarter is 5.1%.
